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Abstract: Breast cancer is the most common type of malignancy diagnosed in women. In the 
metastatic setting this disease is still uncurable. Taxanes represent an important class of antitumor 
agents which have proven to be fundamental in the treatment of advanced and early-stage breast 
cancer, but the clinical advances of taxanes have been limited by their highly hydrophobic 
molecular status. To overcome this poor water solubility, lipid-based solvents have been used 
as a vehicle, and new systemic formulations have been developed, mostly for paclitaxel, which 
are Cremophor-free and increase the circulation time of the drug. ABI-007 is a novel, albumin-
bound, 130-nm particle formulation of paclitaxel, free from any kind of solvent. It has been 
demonstrated to be superior to an equitoxic dose of standard paclitaxel with a signiﬁ  cantly lower 
incidence of toxicities in a large, international, randomized phase III trial. The availability of 
new drugs, such as Abraxane®, in association with other traditional and non-traditional drugs 
(new antineoplastic agents and targeted molecules), will give the oncologist many different 
effective treatment options for patients in this setting. 
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Introduction and background
Breast cancer is the most common type of malignancy diagnosed in women1 with 
more than 180,000 estimated new cases in USA in 2008. Almost one third (32%) 
of all cancers diagnosed in women are breast cancer.1 In the metastatic setting this 
disease is as yet incurable, and the main objectives are the palliative prolongation of 
survival and improvement of quality of life. Other end points are response rate, time 
to progression, time to treatment failure and others; all of these are surrogate end 
points without any real advantage for the patients suffering from a metastatic and 
progressive disease.
Therefore breast cancer continues to be a major health problem although the 
mortality has decreased during recent years, probably because of clinically improved 
new treatments for early-stage disease and the availability of new drugs which have 
shown demonstrable beneﬁ  t for women also with advanced disease.2,3
Taxanes, and in particular the currently available paclitaxel (Taxol®; Bristol-Myers 
Squibb Co, Princeton, NJ, USA)4 and docetaxel5 (Taxotere®; Aventis Pharmaceuticals 
Inc, Bridgewater, NJ, USA), represent an important class of antitumor agents 
which have proved to be fundamental in the treatment of advanced and early-stage 
breast cancer. Both these drugs are included in the treatment regimens for adjuvant 
chemotherapy and are indicated as preferred agents for recurrent and metastatic breast 
cancer by The National Comprehensive Cancer Network (NCCN) clinical practice 
guidelines for breast cancer.6
Taxanes are cell cycle-speciﬁ  c agents that bind with high-afﬁ  nity to microtubules, 
stabilizing and enhancing tubulin polymerization and suppressing spindle microtubule 
dynamics.7–11 This effectively inhibits mitosis, motility, and intracellular transport 
within cancerous cells, leading to apoptotic cell death. Thus these drugs have shown International Journal of Nanomedicine 2009:4 100
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antineoplastic activity against a wide variety of malignancies 
including also non-small-cell lung cancer and ovarian 
cancer.12–14
Paclitaxel is a naturally occurring complex product 
extracted from the bark of the western yew (Taxus 
brevifolia)15–17 and is widely used for the treatment of breast, 
lung, and advanced ovarian cancers10,18,19 while docetaxel was 
originally isolated in a precursor form from the needles of the 
European yew.20
The clinical advances of taxanes have been limited by 
their chemical formulation: they are highly hydrophobic 
molecules. To overcome this poor water solubility, 
lipid-based solvents are used as a vehicle. Solubility of 
paclitaxel is enhanced with a mixture of 50:50 Cremophor 
EL® (CrEL, a non-ionic surfactant polyoxyethylated castor 
oil; BASF, Florham Park, NJ, USA) and ethanol (Taxol® 
and generic equivalents),8 while docetaxel is formulated in 
polysorbate 80 (Tween® 80) and ethanol diluent (Taxotere®). 
For administration, both drugs must be further diluted 5- to 
20-fold with normal saline or 5% dextrose solutions before 
intravenous infusion.
These solvent-based formulations, however, can be 
associated with serious and dose-limiting toxicities.
In particular polyoxyethylated castor oil is biologically and 
pharmacologically active and leaches plasticizers from standard 
intravenous (iv) tubing releasing di(2-ethylhexyl)phthalate 
(DEHP). Its infusion produces histamine release with 
consequent well-described hypersensitivity reactions, 
including anaphylaxis. In early phase I trials 20% to 40% of 
unpremedicated patients were affected10,11 by these reactions. 
Moreover it has been also associated with hyperlipidemia, 
abnormal lipoprotein patterns, aggregation of erythrocytes, 
and prolonged, sometimes irreversible sensory neuropathy 
which may be associated with demyelination and axonal 
degeneration.25,26,29 CrEL can also cause neutropenia.30
The CrEL–paclitaxel formulation thus requires special 
infusion sets (tubing and in-line ﬁ  lters) in order to minimize 
exposure to DEHP. On the other hand, longer infusion times 
(1 to 24 hours, median time 3 hours) with a large volume 
of iv ﬂ  uid and premedication (including dexamethasone, 
diphenhydramine, and cimetidin) help to reduce the risk 
of hypersensitivity reactions. Despite these standard 
precautions hypersensitivity can, however, occur and rarely 
be fatal.21
Infusion schedules of paclitaxel seem to inﬂ  uence its 
clinical effectiveness, too. In fact, longer infusions of the 
drug produce greater clinical efficacy than more rapid 
injections.18
Hypersensitivity reactions can also occur with 
polysorbate 80, though to a lesser extent than with CrEL. 
Polysorbate 80 has also been associated with sometimes 
severe and irreversible sensory and motor neuropathies.31 
Moreover polysorbate 80 can alter membrane ﬂ  uidity,31 
leading to cumulative fluid retention. This unique 
docetaxel toxicity may be reduced by prophylactic 
corticosteroids.32,33
Another important point is that CrEL and polysorbate 
80 may limit tumor penetration with a negative impact on 
efﬁ  cacy. In particular, the formation of large polar micelles 
of CrEL–paclitaxel in the plasma compartment entraps 
the drug and can lead to non-linear pharmacokinetics 
due to decreased drug clearance and decreased volume of 
distribution. This contributes to a lack of dose-dependent 
antitumor activity.22–24,28 Also co-administered drugs, such 
as anthracycline compounds, could be affected by this 
phenomenon.22
Finally, it has been recently demonstrated in vitro that 
polyoxyethylated castor oil inhibits endothelial transcytosis 
of paclitaxel that is mediated by an albumin receptor.27
Therefore during recent years a special effort has been 
made to avoid these problems. New systemic formulations 
are being developed, mostly for paclitaxel, which are highly 
soluble, Cremophor-free and increase the circulation time 
of the drug.
Nanotechnology
Nanotechnology is a new ﬁ  eld of interdisciplinary research 
that has expanded rapidly and widely over the past 10 years 
to help overcome problems in medicine. The term “nano-
technology” was initially introduced to refer to small-scale 
applicative materials (1 to 100 nm).34 Today a combination 
of four criteria have been suggested as essential deﬁ  nitions 
of a nanotechnology tool:35 the “nano” size of the device; its 
man-made character; the properties linked to its nanoscopic 
dimensions; and the ability of “ad hoc” mathematical models 
to predict its speciﬁ  c behavior.
There are many examples of the development of this 
discipline, with tools applicable to different diseases. Most 
well studied are liposomes,36 dendrimers,37,38 super paramag-
netic nanoparticulates,39,40 polymer-based platforms,41,42 gold 
nanoshells,43,44 silicon- and silica-based nanoparticles,45–47 
carbon-60 fullerenes,48 and nanocrystals.49
They can be divided into three generations of compound, 
according to whether or not they were developed to target a 
speciﬁ  c target which is expressed on the tumor cells or the 
endothelium.50International Journal of Nanomedicine 2009:4 101
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Among the “ﬁ  rst generation” vectors (not speciﬁ  cally 
targeted), liposomal drug delivery is certainly the most 
successfully used in the clinic, as demonstrated by liposomal 
doxorubicin for breast, ovarian and Kaposi’s sarcoma.51
In particular for liposomal daunorubicin (DaunoXome®), 
liposomal doxorubicin (D-99, Myocet™), and pegylated 
liposomal doxorubicin (Doxil® and Caelyx®), the delivery 
system enables the enhanced permeation and retention (EPR) 
effect.52,53 In fact the small dimension (300 nm) enables the 
drug to accumulate in the tumor mass by crossing passively 
the fenestrations in the diseased vasculature (passive target-
ing), avoiding or reducing the perfusion of normal tissue 
(mostly the heart with a consequent lower cardiotoxic 
effect).
The “second generation” of therapeutic nanovectors 
are constructed to succeed in “active targeting “of speciﬁ  c 
biological molecules of the tumor cell. The aim is to deliver 
higher drug concentrations to pathologic tissues, sparing 
the normal ones in order to enhance the effect on the tumor, 
thereby reducing systemic toxicity. Chemical binding of 
high afﬁ  nity ligand (eg, folate or prostate-speciﬁ  c membrane 
antigen) on the surface of the nanoparticles,54,55 enhance 
the interaction of nanoparticles with tumor cells, greatly 
improving biodistribution of nanoparticles.
The so-called “third generation” of nanovectors has 
been developed56,57 and is based on a multi-stage strategy. 
The ﬁ  rst-stage particle (biodegradable mesoporous silicon 
microparticles) can circulate within the blood ﬂ  ow. The 
particle speciﬁ  cally chooses the pathologic endothelium 
through a mathematically driven recognition of the 
physico-chemical and geometrical (size, shape) surface 
features. The second-stage nanoparticles that are loaded, 
alone or in a group, to the ﬁ  rst-stage ones, are released 
through the mesoporous material in the tumor mass from 
the site of vascular adhesion (tumor endothelium). These 
latter nanoparticles are sufﬁ  ciently small (20 nm) to easily 
cross the inter-endothelial junctions and diffuse within the 
extravascular compartment, addressing all the possible 
therapies in a more speciﬁ  c manner.
Albumin-bound paclitaxel (ABI-007)
Albumin has a number of characteristics that make it an 
attractive drug vehicle in oncology. It is a natural carrier 
of endogenous hydrophobic molecules (such as vitamins, 
hormones, and other water-insoluble plasma substances), that 
are bound in a reversible non-covalent manner58– 60
Moreover albumin seems to help endothelial transcytosis 
of protein-bound and unbound plasma constituents principally 
through binding to a cell-surface, 60-kDa glycoprotein (gp60) 
receptor (albondin). gp60 binds to caveolin-1 (an intracellular 
protein) with subsequent formation of transcytotic vesicles 
(caveolae) (Figure 1).61–64
Also, osteonectin (known as secreted protein acid rich in 
cysteine [SPARC]) has been shown to bind albumin because 
of a sequence homology with gp60. SPARC, as caveolin-1, is 
often present in some neoplasms (breast, lung, and prostate 
cancer), which could explain why albumin is known to 
accumulate in some tumors and thus facilitates intratumor 
accumulation of albumin-bound drugs.58
Albumin-bound (nab-)paclitaxel ABI-007 (Abraxane®; 
Abraxis BioScience and AstraZeneca) is another example 
of an EPR-based nanovector application for breast cancer. 
It represents one of the strategies adopted to overcome 
the solvent-related problems of paclitaxel and it has been 
recently approved by the US Food and Drug Administration 
for pretreated metastatic breast cancer patients.
ABI-007 is a novel, albumin-bound, 130-nm particle 
formulation of paclitaxel, free from any kind of solvent.66 
It is used as a colloidal suspension derived from the lyophilized 
formulation of paclitaxel and human serum albumin diluted in 
saline solution (0.9% NaCl). In detail human serum albumin 
stabilizes the drug particle at an average size of 130 nm 
which prevents any risk of capillary obstruction and does 
not necessitate any particular infusion systems or steroid/
antihistamine premedication before the infusion.67
Preclinical studies, conducted in athymic mice with 
human breast cancer, demonstrated that ABI-007 has a 
higher penetration into tumor cells with an increased anti-
tumor activity, compared with an equal dose of standard 
paclitaxel.67, 68
A phase I clinical study by Ibrahim, conducted on 
19 patients with solid tumors and breast cancer, showed a 
maximum tolerated dose of ABI-007 about 70% higher than 
that of CrEL paclitaxel formulation (300 mg/m2 for an every 
3 weeks regimen). Dose-limiting toxicities were sensory 
neuropathy, stomatitis, and ocular toxicity (superficial 
keratopathy and blurred vision at a dose of 375 mg/m2). No 
patients experienced hypersensitivity reactions. ABI-007 was 
administered intravenously with no premedication, in shorter 
infusion periods (30 minutes vs 3 hours for polyoxyethylated 
castor oil-based paclitaxel) and with a standard infusion 
device. Moreover, pharmacokinetic parameters showed a 
linear trend.69
A phase II trial conﬁ  rmed that ABI-007 has important 
antitumor activity in patients with metastatic breast 
cancer. The overall response rate (at a dose of 300 mg/m2 International Journal of Nanomedicine 2009:4 102
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every 3 weeks) was 48% for all patients and 64% for 
patients in ﬁ  rst-line therapy. Time to tumor progression was 
26.6 weeks for all patients and 48.1 weeks for patients with 
conﬁ  rmed tumor responses; median overall survival was 
63.6 weeks. No severe ocular events were noted, and other 
common taxane-associated toxicities were less frequent and 
less severe (eg, myelosuppression, peripheral neuropathy, 
nausea, vomiting, fatigue, arthralgia, myalgia, alopecia).70
In a large international randomized phase III study, 
equitoxic doses of ABI-007 (260 mg/m2) and polyoxyethyl-
ated castor oil-based paclitaxel (175 mg/m2) were compared 
in 454 patients with metastitic breast cancer. ABI-007 was 
superior to standard paclitaxel for both overall response 
rate (33% vs 19%, respectively; p = 0.001) and time to 
tumor progression (p = 0.006) in all subgroups of patients, 
but mostly for those receiving the drug as ﬁ  rst-line therapy 
(42% vs 27%, respectively; p = 0.029). Also in this trial the 
incidence of toxicities was signiﬁ  cantly lower in the ABI-007 
group than the polyoxyethylated castor oil-based paclitaxel 
group; in particular, grade 4 neutropenia was lower (10% vs 
21%, respectively; p = 0.001) despite the approximately 50% 
higher dose. On the other hand, grade 3 sensory neuropathy 
was more frequent in the ABI-007 group (10% vs 2%, 
respectively; p = 0.001), but it was easily managed.71
The authors explained the increased antitumor activity of 
ABI-007 by the higher intratumor paclitaxel concentrations 
(as reported in preclinical studies) and higher dose 
administered.72
Neymann et al demonstrated also that weekly dosing of 
ABI-007 is safe and produces minimum toxic adverse effect 
with objective antitumor responses in patients previously 
exposed to paclitaxel.72
Future perspectives
Paclitaxel and docetaxel are hydrophobic antineoplastic 
agents with signiﬁ  cant antitumor activity against a broad 
spectrum of human tumors; in recent years multiple studies 
have suggested the strategic role of taxanes in the treatment 
of breast cancer and other studies have evaluated these agents 
in order to better understand their preclinical and clinical 
pharmacology. Only 5 years ago, results of a clinical trial73 
involving 3121 breast cancer patients showed that 4 cycles 
of paclitaxel after 4 cycles of doxorubicin and cyclophospha-
mide, compared with cyclophosphamide alone, were able to 
improve disease-free survival and overall survival of axillary 
node-positive patients. According to these data the therapy 
for axillary node-positive patients changed dramatically, 
with rapid adoption of paclitaxel plus cyclophosphamide 
as the new gold standard in clinical practice. In a relatively 
short time an impressive improvement occurred in the under-
standing of their mechanism of action, the mechanisms of 
tumor resistance and the toxicity proﬁ  les. Further laboratory 
I                 II                   III 
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Figure 1  Mechanism by which gp60 protein-albumin complex  induces caveolin-1-mediated membrane internalization of plasma components across the vascular endothelium. 
In detail, panel I shows the bond between albumin receptor (gp60) and albumin which recruits and activates caveolin-1. In panel II caveolin-1 leads to membrane invagination 
and internalization of free or protein-bound  plasma molecules. Panel III: the so-formed caveolae mediate transocytosis and the extravascular deposition of their content. International Journal of Nanomedicine 2009:4 103
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and clinical research is necessary to advance the therapy of 
patients with breast cancer in order to improve the therapeutic 
index and the safety of this class of agents. In this context 
the knowledge and investigation of new taxanes constitutes 
today one of the most exciting strategies for improving the 
clinical control of breast cancer in association with other 
cytotoxic agents not usually used in this disease (cisplatin, 
carboplatin, and irinotecan, and molecularly targeted agents, 
such as inhibitors of epidermal growth factor receptor, angio-
genesis, Src tyrosine kinase, and mTOR).
Abraxane® is a Cremophor-free, albumin-bound pacli-
taxel that is approved for the treatment of recurrent breast 
cancer after combination chemotherapy or relapse within 6 
months of adjuvant chemotherapy. Abraxane® consists of 
the active ingredient paclitaxel, which is found in paclitaxel 
and its generic equivalents. However, in the formulation of 
Abraxane®, paclitaxel is delivered in a suspension of albumin 
particles, showing signiﬁ  cant advantages to paclitaxel and 
its generic equivalents, in which polyethoxylated castor oil 
(Cremophor EL®) is used as the solvent.
Moreover Abraxane® has showed strong antitumor 
activity when associated with radiotherapy in a supra-additive 
manner.74 These effects were achieved without increased 
toxicity to normal tissues (the drug dose was 1.5 times higher 
than the maximum tolerated dose of traditional paclitaxel). 
According to these data, there is strong evidence that the 
association of Abraxane® with radiotherapy would improve 
the clinical results of taxane-based chemoradiotherapy. In our 
opinion in the near future this new taxane should be tested in 
large randomized clinical chemoradiotherapy trials.
Above all it is evident that treatment for breast cancer 
in future should be tailored to each patient, trying to select 
treatment strategies for cancer individually based on tumor-
expressing factors and/or genomic and proteomic analysis. 
On the other hand, treatment strategies should be based not 
only on prognostic and predictive factors and prior adjuvant 
chemotherapy, but also on safety proﬁ  le, impact on quality 
of life and patient preference. We believe that in this context, 
tolerability and compliance will probably become the most 
important factors in the future, according to the emerging 
value of quality of life in cancer care. The availability of new 
drugs, such as Abraxane®, in association with other traditional 
and non-traditional drugs (new antineoplastic agents and 
targeted molecules), will give the oncologist many different 
effective treatment options for patients in this setting.
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